Elevar Therapeutics Granted Orphan Medicinal Product Designation by the European Medicines Agency for First-Line Systemic Therapy for Unresectable Hepatocellular Carcinoma
FORT LEE, NEW JERSEY, Aug. 1, 2024 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today announced the European Medicines Agency (EMA) granted Orphan Medicinal Product Designation for rivoceranib in combination with camrelizumab as a first-line treatment option for Unresectable Hepatocellular Carcinoma
